Literature DB >> 292354

Biogenic amine metabolism in Tourette syndrome.

I J Butler, S H Koslow, W E Seifert, R M Caprioli, H S Singer.   

Abstract

Biogenic amine metabolism in the central nervous system of 9 children with Tourette syndrome was evaluated by quantitation of their metabolites in cerebrospinal fluid by a gas chromatographic/mass spectrometric method. Homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) were measured in CSF before and after oral administration of probenecid. Dopamine metabolism appeared defective, as both baseline and accumulated levels of HVA after probenecid were decreased. Serotonin metabolism also appeared defective in some patients with low baseline and low accumulated levels of 5-HIAA after probenecid. Taken together with other clinical features of this disease, the results suggest an underlying disorder of dopamine and serotonin metabolism in Tourette syndrome.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 292354     DOI: 10.1002/ana.410060109

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  18 in total

1.  A controlled study of Tourette syndrome-Revisited: A reply to the letter of Pauls et al.

Authors:  D E Comings; B G Comings
Journal:  Am J Hum Genet       Date:  1988-08       Impact factor: 11.025

Review 2.  The biochemistry of Tourette's syndrome.

Authors:  P R Chokka; G B Baker; R A Bornstein; C M de Groot
Journal:  Metab Brain Dis       Date:  1995-06       Impact factor: 3.584

Review 3.  A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.

Authors:  L L Carpenter; C J McDougle; C N Epperson; L H Price
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 4.  Trace amines and Tourette's syndrome.

Authors:  G B Baker; R A Bornstein; V K Yeragani
Journal:  Neurochem Res       Date:  1993-09       Impact factor: 3.996

5.  PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome.

Authors:  N Turjanski; G V Sawle; E D Playford; R Weeks; A A Lammerstma; A J Lees; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

Review 6.  A controlled study of Tourette syndrome. VII. Summary: a common genetic disorder causing disinhibition of the limbic system.

Authors:  D E Comings
Journal:  Am J Hum Genet       Date:  1987-11       Impact factor: 11.025

7.  Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET.

Authors:  Dean F Wong; James R Brasić; Harvey S Singer; David J Schretlen; Hiroto Kuwabara; Yun Zhou; Ayon Nandi; Marika A Maris; Mohab Alexander; Weiguo Ye; Olivier Rousset; Anil Kumar; Zsolt Szabo; Albert Gjedde; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2007-11-07       Impact factor: 7.853

Review 8.  Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management.

Authors:  Svenja Happe
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Assessment of central dopaminergic function using plasma-free homovanillic acid after debrisoquin administration.

Authors:  M A Riddle; J F Leckman; D J Cohen; M Anderson; S I Ort; K A Caruso; B A Shaywitz
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

10.  Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome.

Authors:  Alicja Lerner; Anto Bagic; Janine M Simmons; Zoltan Mari; Omer Bonne; Ben Xu; Diane Kazuba; Peter Herscovitch; Richard E Carson; Dennis L Murphy; Wayne C Drevets; Mark Hallett
Journal:  Brain       Date:  2012-05-10       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.